Danaher (NYSE:DHR) Raised to “Buy” at StockNews.com

Danaher (NYSE:DHR – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report issued on Monday. Several other analysts also recently weighed in on DHR. JPMorgan Chase & Co. decreased their target price on Danaher from $280.00 to $260.00 and set an “overweight” rating for the company […]

Leave a Reply

Your email address will not be published.

Previous post Iovance Biotherapeutics (NASDAQ:IOVA) Rating Lowered to “Hold” at Truist Financial
Next post Comparing TNF Pharmaceuticals (TNFA) & The Competition